Recently, Ruixin Intelligent Medical (hereinafter referred to as “Ruixinâ€) in Shenzhen Nanshan completed tens of millions of RMB A round of financing. This round of financing is exclusively invested by Jingwei China, and the financing will be used to further deepen and expand the core. The development and marketing of artificial intelligence technology and bio-simulation technology in the field of cardiovascular and cerebrovascular diseases. The previous angel round was invested by Guokejiahe, and the two financing time was only half a year apart.
Different from other artificial intelligence medical imaging companies, Ruixin focuses on the business field and integrates and innovates in the technology field.
Ruixin believes that medical treatment has unique attributes and needs to deeply polish the products in order to better meet the clinical needs, so Ruixin chooses to focus on the cardiovascular and cerebrovascular fields.
At the technical level, Ruixin uses artificial intelligence as the core technology, and combines the top technologies of computational fluid simulation and cloud computing to deeply mine relevant medical data information to obtain cardiovascular and cerebrovascular functional parameters with important diagnostic value. A blood vessel is given the earliest diagnosis and the most accurate treatment.
Simulation migration, from industry to medical
At present, medical imaging AI technology focuses on the identification and judgment of pathological morphology, but it is impossible to speculate on the functional indicators of diseased organs.
In the field of cardiovascular and cerebrovascular diseases, the information that AI technology can provide is limited to information that clinical experts can obtain from images, such as the degree of stenosis of blood vessels extracted from coronary CT images, the attributes of plaques, and the like. However, these morphological information is not sufficient to assess the blood supply function of diseased blood vessels that are highly needed by clinical experts. Currently, such functional indicators can only be obtained through very complicated and costly interventional procedures.
With the rapid development of AI medical image processing technology, is it possible to combine the other top technologies to obtain the functional indicators of blood vessels accurately and non-invasively? The use of computational simulation technology to accurately assess blood flow functional indicators is a unique technological advantage.
Ruixin CEO Zheng Lingwei told the arterial network reporter: "Computational simulation has been widely used in industry, such as in aircraft design, automobile manufacturing, etc. So we think about and explore the application of fluid mechanics to human biological simulation, based on strict The physical laws of the blood can be used to calculate the flow of blood in the blood vessels, so that functional indicators such as blood pressure, flow rate, and shear stress can be obtained. These functional indicators are for accurate disease detection, treatment plan guidance, and postoperative evaluation. All of them have vital value. From the combination of the founding team of the heart (an AI medical imaging expert, two computational simulation experts), we can see the arduous planning: AI deep learning technology, combined with simulation and other top Technology will provide clinical experts with more valuable and in-depth information, rather than just helping doctors do what they can."
However, the human vascular system is very complex and closely related to each organ. How to use fluid mechanics simulation technology to accurately simulate the real situation, including the shape of blood vessels, the role of various organs in the model, and the role of the human end circulation system in the model. Waiting, to provide the most accurate results for each patient, is not an easy task and requires a long time to explore and accumulate.
Zheng Lingqi pointed out: "The two founders of the founding team have more than 10 years of experience in human simulation. After building the basic algorithm model, we apply it to the perfect patient blood vessel data, and continuously adjust the algorithm according to the results. The model that achieves the best match with the actual results to give the doctor the best guidance."
Based on more than a decade of research in the fields of medical imaging and bio-simulation, the company has developed a whole set of algorithms and software for artificial intelligence and fluid simulation, and has achieved considerable accuracy.
On this basis, the first product launched by Ruixin is the diagnostic software for evaluating cardiovascular blood supply function. Only the patient's CT image of the heart is needed. This software can accurately calculate the blood supply function at each position on each blood vessel and generate a diagnostic report.
Based on this diagnostic report, the doctor can decide how to use the medicine, whether to place the stent, and where to place the stent. Around this product, Ruixin also carried out a series of cardiovascular disease research and verification, such as the relationship between cardiovascular stenosis and atherosclerosis; how the impact of blood flow on the blood vessel wall affects the vascular lesion Changes... These problems are difficult to measure with medical instruments and must be accurately quantified through simulation.
Family migration, from the past to the future
The three founders of Ruixin, Zheng Lingyi, Lan Hongzhi and Ma Jun are experts who have obtained doctoral degrees in famous American universities and have worked in related fields for many years.
During the start-up, all three of them took the family back to Shenzhen and made every effort to build China's own intelligent diagnosis platform for cardiovascular and cerebrovascular diseases.
Speaking of this "great migration", Zheng Lingqi said: "Our three families are in the United States for more than ten years. It is a very important decision to return home. It is very grateful to the other half for their support. We know that entrepreneurship is very Difficult things, no courage to break the boat can not be done, so we did not choose the strategy of "two places to run" adopted by many people, but completely returned to the country to invest in the cause. The United States has been leading the technology for a long time in the past, but we We firmly believe that the future of technological innovation is in China, and we are very honored to be involved."
The team's CEO, Zheng Lingqi, holds a bachelor's degree from Beihang University and Johns Hopkins University and has been engaged in biological simulation research for more than 10 years. Years of research and development experience has enabled Zheng Lingyi to develop a plan to use non-invasive screening for cardiovascular disease with simulation technology.
Regarding the original intention of establishing Ruixin, Zheng Lingqi said: "From the perspective of China's national conditions, the incidence and mortality of cardiovascular and cerebrovascular diseases are the highest among all diseases, and as the population ages, the meat of the people's diet The intake is significantly increased, smoking, high blood pressure, and high blood pressure are high. In the next decade or so, cardiovascular and cerebrovascular diseases will bring great pressure to Chinese society. The strain of medical resources makes the workload of clinicians increasingly heavy. The huge patient population and explosive growth have greatly increased the pressure on the state's finances. For the people, the huge expenses of cardiovascular diseases such as coronary heart disease and stroke are also difficult for them to bear. So, we try to create a new series. The technology to help the screening and treatment of cardiovascular and cerebrovascular diseases at a lower cost and higher accuracy to improve the diagnostic efficiency and reduce the burden on patients."
Rui Hong Chief Scientist Lan Hongzhi received his undergraduate degree from Tsinghua University and his Ph.D. in biomedical engineering from Tulane University. He then worked as a researcher at the world's top Stanford University Cardiovascular Simulation Laboratory, at the macro-micro scale biomechanical simulation. With more than 10 years of experience, the cells in the blood are as large as the entire cardiovascular system of the human body.
Cardiovascular disease is a very complicated problem in academic research and clinical application. Each patient has different anatomical structures and physiological conditions from others, so accurate diagnosis and treatment needs to be "depending on people", and Lan Hongzhi's research It covers all aspects of this field, including image analysis based on medical images, three-dimensional modeling of cardiovascular, simulation of blood flow, extraction of hemodynamic functional parameters, and so on.
"Biological simulation has great clinical significance," Lan Hongzhi said. "We can study the pathogenesis of cardiovascular disease, the planning of medical treatment methods, the optimal design of medical devices, and postoperative procedures from the perspective of functional aspects such as fluid mechanics. Prediction of effects, etc., which cannot be done based on anatomical morphology alone. I believe that bio-simulation will bring about a huge change in the medical field, and gradually turn the doctor's experience-based diagnosis and treatment into individualized and precise methods. Quantitative, controllable and predictable direction change, and I hope China can become the protagonist of this change."
Core CTO Ma Jun also obtained an undergraduate degree from Tsinghua University and received his Ph.D. from Johns Hopkins University, the number one in biomedical engineering. He has more than 10 years of experience in machine learning, deep learning, and image processing. He has worked for leading medical device companies such as GE, Siemens, and Da Vinci surgical robots.
When talking about leaving Da Vinci's surgical robots to create a heart, Ma Jun said: "I and Ling Xiao appreciate each other during Hopkins's reading of Bo, and often exchange views on cutting-edge technology. For cardiovascular and cerebrovascular diagnostic platforms. This vision, our brothers and sisters talked all night long nights, from the technical collision and integration of the fields in the two sides, to the value that products can bring to patients in the future, to the feelings of doing something for the country, always talking about the day. Quickly. Now look back at the history of medical imaging technology development. If the first half of the first half is a hardware system-based device update, the second half of the theme should be the deep mining and analysis of image information based on artificial intelligence. We believe that artificial intelligence in the cardiovascular and cerebrovascular fields can really help doctors."
To accurately diagnose cardiovascular and cerebrovascular diseases, automatic, accurate and rapid analysis of medical images is an essential and critical step. Ma Jun's many years of medical imaging and deep learning experience have enabled AI technology to automate the identification, reconstruction and blood flow simulation of blood vessels. He and the team developed a unique and advanced deep learning algorithm based on a large amount of image data, which greatly improved the calculation accuracy and increased the speed by several times.
From left to right, Ma Jun, Zheng Lingqi, Lan Hongzhi, all three founders have obtained top school PHD degrees in North America.
Artificial intelligence, from improving efficiency to seeing nothing
Ruixin believes that the long-term positioning of artificial intelligence is not only to improve the efficiency and accuracy of clinicians in the existing processes, but more importantly, it is combined with bio-simulation and other technologies to provide doctors with new information that cannot be directly judged by the eyes. The new knowledge that can't be obtained, from “helping doctors to see†to “seeing for doctorsâ€, finally realizes the vision of “seeing nowhereâ€.
However, this journey has a long way to go. To accomplish these ultimate goals, we need to do basic steps such as algorithms and data. Therefore, the goal at this stage is to apply artificial intelligence and mechanics simulation to deep mining medical data. Enrich information and provide faster and more accurate analysis results for clinicians to make decisions.
Sun Weiwei, senior investment manager of Jingwei China, said: "We continue to pay attention to the application of computer technology in various fields such as biomedicine, imaging, electronic medical records, etc. Ruixin Medical is the latest layout of Jingwei in the medical + AI direction. Compared with radiologists, clinicians The diagnosis needs are more complicated, and the screening problem is solved by intelligent diagnosis. It has high clinical economic value. In the short time, Core has already cooperated with top domestic experts to establish multiple product lines, and expects that Core can become a cardiovascular tube. A platform-based company in the field of intelligent diagnostics."
Liu Junpeng, the vice president of Angel Wheel Investment, said: "Ruixin intelligent products have great market application prospects. From a clinical point of view, high precision and convenient detection. It can greatly reduce the hospitalization time and non-invasive detection effect. It is comparable to the detection accuracy that can be achieved by intervention.
In terms of social benefits, it can save a large number of patients from unnecessary interventions, thus saving medical insurance and patient expenses. From the point of view of product characteristics, Ruixin Smart Products is the perfect combination of AI and medical imaging, which can effectively help existing medical care, and Ruixin Smart aims to build a technical platform for cardiovascular and cerebrovascular fields and develop a series of AI+ medical subdivision products. â€
*The picture in the text is provided by the respondent.
Plant extracts powder have the characteristics of green, environmental protection, and safety, and it has been emphasized in culture applications, and it has gradually become a research hotspot, and it has gradually become a positive and productive alternative to antibiotics after feed resistance prohibition.
Plant Extract (PE) is a single or mixed substance obtained from plants by physical and chemical means, which contains polyphenols, alkaloids, polysaccharides, essential oils and other active substances. Polyphenols are the most abundant active components of PE, which have antioxidant, anti-inflammatory, antibacterial and anti-tumor activities. Similarly, other components (e.g., flavonoids, alkaloids) have multiple biological functions.
The Catalogue of Feed Ingredients contains 117 natural plant extracts, such as anise oil, basil oil, cinnamon oil, clove bud oil, orange oil, lost essential oil, oregano oil, and thyme essential oil.
Plant extracts powder is rich in bioactive substances, which has the functions of regulating nutrient metabolism, antioxidant, immune regulation, antibacterial and insect repellent. It is a green and healthy additive, and has a good effect on promoting the healthy growth of piglets. It plays an important role in reducing the use of antibiotics and promoting the development of healthy aquaculture.
plant extract powder supplier,plant extract powder factory,buy plant extract powder,plant extract powder capsules
Shaanxi YXchuang Biotechnology Co., Ltd , https://www.peptide-nootropics.com